Chronic Lymphocytic Leukemia Articles | Page 2

Venetoclax Demonstrates Strong Activity in CLL After BCR Inhibitor
Patients with relapsed/refractory CLL who failed on previous treatment with a BCR signaling pathway inhibitor had an overall response rate of 65% following treatment with venetoclax (Venclexta).
Promising Results in CLL for Frontline Ibrutinib Plus Chemoimmunotherapy
Adding ibrutinib to a standard frontline chemoimmunotherapy for chronic lymphocytic leukemia induced negative minimum residual disease status in bone marrow for 83% of patients.
Combinations Have Potential to Shift CLL Treatment Paradigm
Richard Furman, MD, discusses the current management of chronic lymphocytic leukemia and the future of combinations, including venetoclax and ibrutinib, for this patient population.
CLL in the Era of Targeted Therapies
Over the past few years, remarkable advances have been achieved in the field of chronic lymphocytic leukemia by rationally targeting pathways overexpressed and used by the malignant clone for proliferation and survival.
The combination of venetoclax and rituximab reduced the risk of disease progression or death by 83% versus bendamustine plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. 
Rituximab Leads to Faster Response in CLL, But PFS Not Improved
Despite a faster time to complete remission, the addition of rituximab (Rituxan) to ibrutinib (Imbruvica) did not improve PFS or overall survival OS compared with ibrutinib alone in patients with CLL. 
Ibrutinib/Venetoclax Combo Impresses in Early CLL Data
The combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) elicited a complete response (CR) or CR with incomplete hematologic recovery rate of 47% for patients with relapsed/refractory chronic lymphocytic leukemia.
Treatment Strategies Expanding for Elderly Patients With CLL
Jacqueline Claudia Barrientos, MD, discusses the appropriate treatment strategies for elderly patients with chronic lymphocytic leukemia.
Umbralisib, Ublituximab, Ibrutinib Triplet Reaches 100% Response in CLL
Loretta J. Nastoupil, MD, discusses the study of the triplet of ublituximab, umbralisib (TGR-1202) and ibrutinib in CLL. 
Acalabrutinib Among Exciting Options Emerging in CLL
Jacqueline Claudia Barrientos, MD, discusses emerging treatment options in CLL.
Publication Bottom Border
Border Publication